Research programme: anxiety and neurological disorder therapeutics - AstraZeneca
Alternative Names: 5-HT1A receptor antagonists - AstraZeneca; AZ 12320927Latest Information Update: 04 Nov 2017
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Karolinska Institute; University of Texas Southwestern Medical Center
- Class
- Mechanism of Action 5-HT1A serotonin receptor antagonists; Opioid delta receptor agonists; Serotonin 1B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Anxiety disorders; Major depressive disorder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Sweden
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in United Kingdom
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA